Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

– Designation is an important step toward bringing this potentially life-changing therapy to European patients –
– EU Orphan Drug Designation is the first regulatory designation for a gorilla...

Related Keywords

United States ,Stevenm Harasym ,Helen Sabzevari ,Exchange Commission ,Prnewswire Precigen Inc ,Precigen Inc ,European Commission ,Drug Administration ,Nasdaq ,Drug Designation For The Company ,European Union ,Committee For Orphan Medicinal Products ,European Medicines Agency ,Drug Designation ,Orphan Drug Designation ,United States Food ,Breakthrough Therapy Designation ,Orphan Medicinal ,Biologics License Application ,Advancing Medicine ,Annual Report ,Otolaryngol Head Neck Surg ,Recurrent Respiratory Papillomatosis ,Developing Country Review ,Health Med Ther ,Head Neck Surg ,Markets ,